Million Arefayene

795 total citations
13 papers, 451 citations indexed

About

Million Arefayene is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Million Arefayene has authored 13 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Million Arefayene's work include Pharmacogenetics and Drug Metabolism (6 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Estrogen and related hormone effects (2 papers). Million Arefayene is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Estrogen and related hormone effects (2 papers). Million Arefayene collaborates with scholars based in United States, Switzerland and South Korea. Million Arefayene's co-authors include Todd C. Skaar, David A. Flockhart, Durai B. Subramani, Gargi D. Basu, Judy Bradley, Zeruesenay Desta, Pinku Mukherjee, Teresa L. Tinder, Gabor G. Illei and Kazuki Takada and has published in prestigious journals such as The Journal of Immunology, Neurology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Million Arefayene

12 papers receiving 442 citations

Peers

Million Arefayene

ONCOL

PHARM

IMMUN

PHARM

Yuko Tsukamoto Japan

Tomoaki Higuchi Japan

Shunji Matsuki Japan

Andrew P. Beelen United States

Jennifer Dong United States

Ruth Roberts United Kingdom

Herbert Birnboeck Switzerland

Kjeld Schmiegelow Denmark

Zhengyu Xue United States

Woo‐Young Kim South Korea

Yuko Tsukamoto Japan

Million Arefayene

213 ×1.2

192 ×1.2

ONCOL

157 ×1.5

PHARM

66 ×0.7

IMMUN

33 ×0.8

PHARM

Citations per year, relative to Million Arefayene Million Arefayene (= 1×) peers Yuko Tsukamoto

Countries citing papers authored by Million Arefayene

Since Specialization

Citations

This map shows the geographic impact of Million Arefayene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Million Arefayene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Million Arefayene more than expected).

Fields of papers citing papers by Million Arefayene

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Million Arefayene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Million Arefayene. The network helps show where Million Arefayene may publish in the future.

Co-authorship network of co-authors of Million Arefayene

This figure shows the co-authorship network connecting the top 25 collaborators of Million Arefayene. A scholar is included among the top collaborators of Million Arefayene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Million Arefayene. Million Arefayene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Zuo, Peiying, Million Arefayene, Wei‐Jian Pan, Tomoko Freshwater, & Jonathan Monteleone. (2024). A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers. Clinical Pharmacology in Drug Development. 13(7). 770–781. 1 indexed citations

Puryear, Corey B., Prashant Bansal, Balaji Sriram, et al.. (2023). PRAX-562-102: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers (P4-9.011). Neurology. 100(17_supplement_2).

Arefayene, Million, Majd Mouded, Guolin Zhao, et al.. (2018). Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF). PA596–PA596. 5 indexed citations

Brian, William R., Larry M. Tremaine, Million Arefayene, et al.. (2016). Assessment of Drug Metabolism Enzyme and Transporter Pharmacogenetics in Drug Discovery and Early Development: Perspectives of the I-Pwg. Pharmacogenomics. 17(6). 615–631. 7 indexed citations

Mukherjee, Pinku, Gargi D. Basu, Teresa L. Tinder, et al.. (2009). Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition. The Journal of Immunology. 182(1). 216–224. 81 indexed citations

Arefayene, Million, Santosh Philips, Zeruesenay Desta, et al.. (2009). Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenetics and Genomics. 19(6). 464–476. 31 indexed citations

Tinder, Teresa L., Durai B. Subramani, Gargi D. Basu, et al.. (2008). MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma. The Journal of Immunology. 181(5). 3116–3125. 93 indexed citations

Shin, Jae‐Gook, Ji‐Hong Shon, Million Arefayene, et al.. (2006). Possible interethnic differences in quinidine‐induced QT prolongation between healthy Caucasian and Korean subjects. British Journal of Clinical Pharmacology. 63(2). 206–215. 33 indexed citations

Chalasani, Naga, Todd C. Skaar, Dhanashri Kolwankar, et al.. (2005). Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression*. Clinical Pharmacology & Therapeutics. 77(3). 178–188. 46 indexed citations

10.

Takada, Kazuki, Million Arefayene, Zeruesenay Desta, et al.. (2004). Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis & Rheumatism. 50(7). 2202–2210. 119 indexed citations

11.

Arefayene, Million, Todd C. Skaar, X.-J. Zhao, et al.. (2003). Sequence diversity and functional characterization of the 5???-regulatory region of human CYP2C19. Pharmacogenetics. 13(4). 199–206. 12 indexed citations

12.

Desai, Mehul, José E. Tanus‐Santos, J. Christopher Gorski, et al.. (2003). Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. The Pharmacogenomics Journal. 3(2). 105–113. 21 indexed citations

13.

Arefayene, Million, X.-J. Zhao, José E. Tanus‐Santos, et al.. (2003). Functional characterization of the 5′‐regulatory region of human CYP2C19. Clinical Pharmacology & Therapeutics. 73(2). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact